Defendant
10 cases as defendant.
Lupin Pharmaceuticals, Inc. is the U.S. wholly-owned subsidiary of Lupin Limited, an Indian multinational pharmaceutical company. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. was incorporated in 2002 and commenced U.S. operations in 2003. The parent company, Lupin Limited, was founded in 1968 and is a public company listed on the Bombay Stock Exchange and National Stock Exchange in India. Lupin Pharmaceuticals, Inc. had an estimated annual revenue of $1.1 billion and approximately 5,709 employees.
The company is an operating pharmaceutical firm dedicated to delivering high-quality branded and generic medications across the United States. Its extensive product portfolio includes generics, complex generics, branded formulations, biosimilars, over-the-counter drugs, and active pharmaceutical ingredients (APIs). Lupin Pharmaceuticals, Inc. focuses on a wide range of therapeutic areas, including cardiovascular, diabetology, asthma, pediatrics, anti-infectives, women's health, and respiratory care. Notable products include Suprax (a pediatric antibiotic), Solosec (for bacterial vaginosis and trichomoniasis), and generic versions of drugs for conditions like COPD and type 2 diabetes.
In terms of patent litigation, Lupin Pharmaceuticals, Inc. operates as a defendant. Its single tracked case in the U.S. patent litigation database, Otsuka Pharmaceutical Co., Ltd. v. Lupin Ltd. et al., shows the company as a defendant. This posture is consistent with an operating pharmaceutical company that faces patent challenges, often related to generic drug approvals.
The sole tracked case involving Lupin Pharmaceuticals, Inc. is Otsuka Pharmaceutical Co., Ltd. v. Lupin Ltd. et al. in the U.S. District Court for the District of Delaware. This type of litigation is common in the pharmaceutical industry, frequently involving disputes over patents protecting branded drugs challenged by generic manufacturers. Lupin has a history of receiving FDA approvals for various medications and continues to expand its product offerings.
Neurelis asserted U.S. Patent 12337061 and additional patent(s) against Lupin entities in the District of Delaware, relating to ANDA No. 220394 for diazepam nasal spray strengths 5, 7.5, and 10 mg/spray. The case is pending with a bench trial set for the week of 2027-03-01.
Neurelis, Inc.'s ANDA suit against Lupin entities. Aggregator pages list the '664 patent among the consolidated Neurelis ANDA family, but the individual docket has not been independently confirmed to assert it.
Jazz sued Lupin over Lupin's ANDA No. 215911 for generic Xywav; the complaint expressly lists the '426 patent among ten patents-in-suit. Lupin answered and counterclaimed; the case was consolidated with later Lupin suits and the Teva action, with no final merits judgment on the '426 patent found.
Hatch-Waxman ANDA infringement action by Sun against Lupin concerning Lupin's ANDA No. 211239 for bromfenac ophthalmic solution 0.075%. The court found the ’999 patent not literally infringed, obvious, and indefinite, but the case was settled and dismissed with prejudice in February 2022, with the September 30, 2021 opinion vacated.
Jazz Pharmaceuticals, Inc. et al. sued Lupin entities in D.N.J. involving the '106 patent. The case was closed and later settled June 12, 2018 per Hagens Berman complaint; docket noted termination Jan. 15, 2016 per L. Civ. R. 11.2 certification.
Lilly sued Lupin for infringement of US 5,023,269 in the Cymbalta/duloxetine HCl ANDA litigation. The case was dismissed by stipulation/consent order on April 27, 2011, converting Paragraph IV certifications to Paragraph III, with no appeal.
The District Court found Lupin did not infringe US Patent 8501730 and US Patent 8273735, with US Patent 8273735 also found invalid as obvious. On appeal, the Federal Circuit affirmed the non-infringement finding for 8501730, but controversially determined its asserted method claims were invalid as obvious.
Action asserting the '708 patent; settled.
Second action against Lupin asserting the '708 patent; settled.
Filed after Lupin's July 23, 2015 Paragraph IV notice. The complaint confirms the '650 patent as a patent-in-suit; settled.